870483-87-7 | Gw2580

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$24.00	$17.00
10mg	98%	in stock	$63.00	$45.00
25mg	≥99%	in stock	$149.00	$105.00
50mg		in stock	$184.00	$129.00
100mg		in stock	$217.00	$152.00
250mg	95%	in stock	$246.00	$172.00
1g	95%	in stock	$649.00	$454.00

Description

• Catalog Number: AB48008
• Chemical Name: Gw2580
• CAS Number: 870483-87-7
• Molecular Formula: C20H22N4O3
• Molecular Weight: 366.4137
• MDL Number: MFCD12024701
• SMILES: COc1cc(ccc1OCc1ccc(cc1)OC)Cc1cnc(nc1N)N

Computed Properties

• Complexity: 433
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 7
• XLogP3: 2.6

Literature

• Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.

  Brain : a journal of neurology 20160301

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

  The Biochemical journal 20130415

• Regulation of microglial proliferation during chronic neurodegeneration.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20130206

• Role of cell cycle-associated proteins in microglial proliferation in the axotomized rat facial nucleus.

  Glia 20120401

• Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.

  Journal of clinical immunology 20111201

• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

  Nature biotechnology 20111101

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

  European journal of medicinal chemistry 20110601

• Macrophage-colony stimulating factor and interleukin-34 induce chemokines in human whole blood.

  Cytokine 20101201

• Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

  Chemistry & biology 20101124

• Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis.

  The Journal of pathology 20100501

• Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.

  Blood 20100218

• c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.

  Arthritis research & therapy 20100101

• Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats.

  The Journal of pharmacology and experimental therapeutics 20080701

• A quantitative analysis of kinase inhibitor selectivity.

  Nature biotechnology 20080101

• A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

  Proceedings of the National Academy of Sciences of the United States of America 20071218

• Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.

  Proceedings of the National Academy of Sciences of the United States of America 20051101